ClinicalTrials.gg
Status unknownNCT03774199NPOCSUpdated Mar 21, 2019

NightOwl Pulse Oximeter Calibration Study

An interventional study of NightOwl in Pulse Oximeter Calibration, sponsored by Ectosense NV. Status unknown at 1 site in Belgium. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-21.

Sponsored by Ectosense NV (part of ResMed) · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
13 Years and older
Sex
All
01

Study summary

Calibration of a software module that computes SpO2 based on photoplethysmography (PPG) traces acquired by a reflectance-based pulse oximeter which can be placed on the index finger or the forehead.

The study is designed in accordance with Medical electrical equipment - Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment (ISO 80601- 2-61:2011)

02

Conditions studied

  • Pulse Oximeter Calibration
03

In context

Lead sponsor

Ectosense NV is the lead sponsor of 6 studies on the registry; none are open to participants now.

First submitted before Ectosense NV became part of ResMed.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy subjects (ASA 1 and ASA 2) upon signing the . (ASA : 's health score)

Exclusion criteria

Exclusion Criteria:

  • smokers or individuals exposed to high levels of carbon monoxide that result in elevated carboxyhaemoglobin levels.
  • individuals subject to conditions that result in elevated levels of methaemoglobin.
  • individuals with arterial cannulation or hypoxia at FiO2 = 0,21
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Pulse oximeter calibration population

    Device: NightOwl

Interventions

  • DeviceNightOwl

    The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived

06

What researchers measure

Primary outcomes

  1. A_rms determination

    After calibration of the NightOwl SpO2 software module, the A_rms metric will be computed. This metric constitutes the performance metric proposed by ISO 80601-2-61:2011 Annex CC: Determination of accuracy. This metric captures the bias and precision of the computed SpO2 values compared to the benchmark.

    Time frame: Within 3 months after subject recruitment, the calibration and ARMS determination should have been performed.

07

Study locations

1 of 1 sites recruiting
  • CMC
    Genk, Limburg 3600, Belgium
    Recruiting
    • Rafael De Jongh, MD PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2018 (actual). Primary completion is estimated for Dec 2019, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Dec 12, 2018
StartActual
Dec 14, 2018
Primary completionEst.
Dec 14, 2019
CompletionEst.
Apr 14, 2020
Last update
Mar 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03774199
Lead sponsor
Ectosense NV
Responsible party
Sponsor
First posted
Dec 12, 2018
Start date
Dec 14, 2018
Primary completion
Dec 14, 2019 (estimated)
Completion
Apr 14, 2020 (estimated)
Last update
Mar 21, 2019

Study contacts

Frederik Roger Massie, ir
Contact
frederik.massie@ectosense.com
474942710 ext. +32

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion